摘要
目的比较两性霉素B和伏立康唑对临床真菌的体外抗菌活性。方法用两性霉素B和伏立康唑的E-test条对分离自临床标本的116株真菌进行体外药敏试验,其中热带念珠菌15株,光滑念珠菌14株,近平滑念珠菌11株,克柔念珠菌6株,新生隐球菌8株,阿萨希毛孢子菌9株,烟曲霉29株,黄曲霉15株,黑曲霉1株,镰刀菌属7株,根霉属1株,以ATCC22019光滑念珠菌为质控菌株。结果两性霉素B对阿萨希毛孢子菌、镰刀菌、黄曲霉的MIC90均为64μg/ml,对其余受试菌株的MIC90均≤1μg/ml,伏立康唑对镰刀菌的MIC90为64μg/ml,对大部分受试菌株的MIC90均≤2μg/ml。结论除对某些真菌可能无效外,两性霉素B和伏立康唑可能适用于治疗大多数的真菌感染。
Objective To compare the antifungal susceptibility of amphotericin B and voriconazole against clinical isolates. Methods In vitro antifungal susceptibility test was performed to using E-test strips of amphotericin B and voriconazole 116 clinical isolates, including 15 strains of Candida tropicalis , 14 Candida glabrata , 11 Candida parapsilosis , 6 Candida krusei , 8 Cryptococcus neoformans ,9 Trichosporon asahii , 29 Aspergillus fumigatus , 15 Aspergillus flavus , 7 Fusariurn spp. , 1 Aspergillus niger ,1 Rhizopus sp. and Candida glabrata ATCC22019 selected was as control. Results MIC90 of amphotericin B against Trichosporon asahii , Fusariurn spp. and Aspergillus flavus were all 64 μg/ml, while MIC90 of other strains tested were less than 1 μg/ml. MIC90 of voriconazole against Fusarium spp. was 64 μg/ml ,otherwise the MIC90 of voriconazole aginst most strains were less than 2 μg/ml. Conclusions Amphotericin B and voriconazole may be used to treat infections caused by most yeasts and moulds.
出处
《中国真菌学杂志》
2007年第3期137-139,共3页
Chinese Journal of Mycology
